Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia

Karena M. Meehan, Huei Wang, Stacy R. David, Jennifer R. Nisivoccia, Barry Jones, Charles M. Beasley, Peter D. Feldman, Jacobo E. Mintzer, Louise M. Beckett, Alan Breier

Research output: Contribution to journalArticle

168 Citations (Scopus)

Abstract

This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia. At 2 h, olanzapine (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES), and both 5.0 mg olanzapine and lorazepam showed superiority to placebo on the Cohen-Mansfield Agitation Inventory. At 24 h, both olanzapine groups maintained superiority over placebo on the PANSS-EC; lorazepam did not. Olanzapine (5.0 mg) and lorazepam improved ACES scores more than placebo. Simpson-Angus and Mini-Mental State Examination scores did not change significantly from baseline. Sedation (ACES ≥8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment. No significant differences among treatment groups were seen in extrapyramidal symptoms or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis. Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation.

Original languageEnglish (US)
Pages (from-to)494-504
Number of pages11
JournalNeuropsychopharmacology
Volume26
Issue number4
DOIs
StatePublished - 2002

Fingerprint

olanzapine
Lorazepam
Double-Blind Method
Dementia
Placebos
Alzheimer Disease
Vascular Dementia
Vital Signs
Intramuscular Injections
Dizziness
Inpatients
Therapeutics
Safety
Equipment and Supplies

Keywords

  • Agitation
  • Dementia
  • Intramuscular injections
  • Lorazepam
  • Olanzapine
  • PANSS

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo : A double-blind, randomized study in acutely agitated patients with dementia. / Meehan, Karena M.; Wang, Huei; David, Stacy R.; Nisivoccia, Jennifer R.; Jones, Barry; Beasley, Charles M.; Feldman, Peter D.; Mintzer, Jacobo E.; Beckett, Louise M.; Breier, Alan.

In: Neuropsychopharmacology, Vol. 26, No. 4, 2002, p. 494-504.

Research output: Contribution to journalArticle

Meehan, Karena M. ; Wang, Huei ; David, Stacy R. ; Nisivoccia, Jennifer R. ; Jones, Barry ; Beasley, Charles M. ; Feldman, Peter D. ; Mintzer, Jacobo E. ; Beckett, Louise M. ; Breier, Alan. / Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo : A double-blind, randomized study in acutely agitated patients with dementia. In: Neuropsychopharmacology. 2002 ; Vol. 26, No. 4. pp. 494-504.
@article{6c00dc23c9874030aa688867bff43c36,
title = "Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia",
abstract = "This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia. At 2 h, olanzapine (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES), and both 5.0 mg olanzapine and lorazepam showed superiority to placebo on the Cohen-Mansfield Agitation Inventory. At 24 h, both olanzapine groups maintained superiority over placebo on the PANSS-EC; lorazepam did not. Olanzapine (5.0 mg) and lorazepam improved ACES scores more than placebo. Simpson-Angus and Mini-Mental State Examination scores did not change significantly from baseline. Sedation (ACES ≥8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment. No significant differences among treatment groups were seen in extrapyramidal symptoms or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis. Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation.",
keywords = "Agitation, Dementia, Intramuscular injections, Lorazepam, Olanzapine, PANSS",
author = "Meehan, {Karena M.} and Huei Wang and David, {Stacy R.} and Nisivoccia, {Jennifer R.} and Barry Jones and Beasley, {Charles M.} and Feldman, {Peter D.} and Mintzer, {Jacobo E.} and Beckett, {Louise M.} and Alan Breier",
year = "2002",
doi = "10.1016/S0893-133X(01)00365-7",
language = "English (US)",
volume = "26",
pages = "494--504",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo

T2 - A double-blind, randomized study in acutely agitated patients with dementia

AU - Meehan, Karena M.

AU - Wang, Huei

AU - David, Stacy R.

AU - Nisivoccia, Jennifer R.

AU - Jones, Barry

AU - Beasley, Charles M.

AU - Feldman, Peter D.

AU - Mintzer, Jacobo E.

AU - Beckett, Louise M.

AU - Breier, Alan

PY - 2002

Y1 - 2002

N2 - This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia. At 2 h, olanzapine (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES), and both 5.0 mg olanzapine and lorazepam showed superiority to placebo on the Cohen-Mansfield Agitation Inventory. At 24 h, both olanzapine groups maintained superiority over placebo on the PANSS-EC; lorazepam did not. Olanzapine (5.0 mg) and lorazepam improved ACES scores more than placebo. Simpson-Angus and Mini-Mental State Examination scores did not change significantly from baseline. Sedation (ACES ≥8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment. No significant differences among treatment groups were seen in extrapyramidal symptoms or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis. Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation.

AB - This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia. At 2 h, olanzapine (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES), and both 5.0 mg olanzapine and lorazepam showed superiority to placebo on the Cohen-Mansfield Agitation Inventory. At 24 h, both olanzapine groups maintained superiority over placebo on the PANSS-EC; lorazepam did not. Olanzapine (5.0 mg) and lorazepam improved ACES scores more than placebo. Simpson-Angus and Mini-Mental State Examination scores did not change significantly from baseline. Sedation (ACES ≥8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment. No significant differences among treatment groups were seen in extrapyramidal symptoms or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis. Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation.

KW - Agitation

KW - Dementia

KW - Intramuscular injections

KW - Lorazepam

KW - Olanzapine

KW - PANSS

UR - http://www.scopus.com/inward/record.url?scp=0036195522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036195522&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(01)00365-7

DO - 10.1016/S0893-133X(01)00365-7

M3 - Article

C2 - 11927174

AN - SCOPUS:0036195522

VL - 26

SP - 494

EP - 504

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 4

ER -